Data Insights

GNC-035 by Systimmune for Non-Hodgkin Lymphoma: Likelihood of Approval

GNC-035 is under clinical development by Systimmune and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - GNC-035 in Non-Hodgkin Lymphoma

Data Insights

Izalontamab by Systimmune for Lung Adenocarcinoma: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Lung Adenocarcinoma

Data Insights

Izalontamab by Systimmune for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Oral Cavity (Mouth) Cancer

Data Insights

Izalontamab by Systimmune for Oropharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Oropharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Nasopharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Nasopharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Laryngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Laryngeal Cancer

Data Insights

Izalontamab by Systimmune for Hypopharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Hypopharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Colon Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Colon Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Colon Cancer

Data Insights

Izalontamab by Systimmune for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Triple-Negative Breast Cancer (TNBC)

Data Insights

Danvilostomig by Systimmune for Gastric Cancer: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Data Insights

Izalontamab by Systimmune for Lung Adenocarcinoma: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase I...

Data Insights

Izalontamab by Systimmune for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Data Insights

Izalontamab by Systimmune for Oropharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...

Data Insights

Izalontamab by Systimmune for Nasopharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...

Data Insights

Izalontamab by Systimmune for Laryngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...

Data Insights

Izalontamab by Systimmune for Hypopharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...

Data Insights

Izalontamab by Systimmune for Colon Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Colon Cancer. According to GlobalData, Phase I...

Data Insights

Izalontamab by Systimmune for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Data Insights

BLM-02D1 by Systimmune for Solid Tumor: Likelihood of Approval

BLM-02D1 is under clinical development by Systimmune and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BLM-02D1 in Solid Tumor

Data Insights

BLM-02D1 by Systimmune for Non-Small Cell Lung Cancer: Likelihood of Approval

BLM-02D1 is under clinical development by Systimmune and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BLM-02D1 in Non-Small Cell Lung Cancer